EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Low Synovial Lymphocyte Percentage as a Novel Diagnostic Marker of Periprosthetic Joint Infection

Assil-Ramin Alimy, Jonah Sijakov, Nico Maximillian Jandl, Patricia Bartsch, Christian Ries, Jan Hubert, Eva Tolosa, Holger Rohde, Johannes Keller, Frank Timo Beil, Tim Rolvien

JBJS Open Access · 2025-10 · 10 (4)

DOI: 10.2106/jbjs.oa.25.00241 ↗
AbstractBibliografische Angaben

Abstract

Objectives: Correctly diagnosing periprosthetic joint infection (PJI) remains a major clinical challenge. While acute PJI is straightforward to identify because of its pronounced clinical presentation, chronic infections remain challenging to detect since clinical signs are subtle and standard criteria lack sensitivity. By analyzing a wide range of serum and synovial parameters in patients undergoing revision arthroplasty, we sought to identify the most accurate diagnostic PJI markers. Methods: A retrospective analysis of 400 patients undergoing knee or hip revision arthroplasty, including 145 patients who had PJI and 255 patients who had aseptic failure, was conducted. Diagnosis of PJI was established using the 2018 International Consensus Meeting criteria. A comprehensive evaluation of medical records, serum, and synovial biomarkers was performed. For each marker, receiver operating characteristic curves, calculating the area under the curve and optimal cutoff values, were determined. Results: Synovial biomarkers such as alpha-defensin and C-reactive protein did not demonstrate superior diagnostic performance compared with polymorphonuclear neutrophil (PMN) count and percentage. Importantly, low synovial lymphocyte percentage (

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →